TACSTD2 and urinary bladder cancer: The TROP2 (Trophoblast cell surface antigen 2)-directed antibody-drug conjugate Sacituzumab govitecan (SG; TrodelvyTM) is a new therapeutic option for bladder cancer patients with metastatic disease (4).